TSHR; | |
ACHE; | |
TDP1; HPGD; USP2; BRCA1; | |
MAPK1; ATM; PTK2B; | |
CA2; CA12; CA13; CA1; CA9; CA7; CA5A; CA3; CA14; CA5B; CA6; | |
PPARA; PPARD; | |
CASP1; CASP7; | |
TLR2; | |
TP53; NFKB1; | |
KMT2A; | |
ABCC1; | |
XPO1; HTT; RAB9A; NPC1; LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; HBB; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | BRCA1 | Breast cancer type 1 susceptibility protein | P38398 | CHEMBL5990 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | ATM | Serine-protein kinase ATM | Q13315 | CHEMBL3797 |
Protein Kinase | PTK2B | Protein tyrosine kinase 2 beta | Q14289 | CHEMBL5469 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | XPO1 | Exportin-1 | O14980 | CHEMBL5661 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.099E-13 | 6.939E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 7.546E-13 | 9.129E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.131E-12 | 5.751E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.896E-11 | 1.376E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.125E-11 | 1.493E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.654E-11 | 4.391E-08 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.383E-10 | 4.149E-07 | BRCA1, CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, KMT2A, PPARA, PPARD, TP53 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 1.272E-09 | 5.651E-07 | CYP1A1, CYP2A13, CYP2A6, CYP2D6 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.569E-08 | 5.694E-06 | ATM, CASP1, CYP1A1, LMNA, PPARA, PPARD, PTK2B, TLR2, TP53 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.782E-08 | 6.258E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.125E-08 | 1.787E-05 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 8.488E-08 | 2.340E-05 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 4.445E-07 | 1.100E-04 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 6.087E-07 | 1.426E-04 | CA2, CA9, CYP1A2, FABP3, HPGD, NFKB1, NPC1, PPARA, PTK2B, TLR2, TSHR |
CC | GO:0044464; cell part | GO:0044444; cytoplasmic part | 2.487E-06 | 5.362E-04 | ACHE, ATM, BRCA1, CA1, CA13, CA2, CA3, CA5A, CA5B, CA7, CASP1, CASP7, CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, FABP2, FABP3, FABP4, FABP5, HBB, HPGD, HTT, KMT2A, LMNA, MAPK1, MAPT, NFKB1, NPC1, PTK2B, RAB9A, TLR2, TP53, USP2, XPO1 |
BP | GO:0051179; localization | GO:0006869; lipid transport | 4.663E-06 | 9.579E-04 | ABCC1, ATM, FABP3, HTT, NPC1, PPARA, PPARD |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.132E-26 | 2.464E-22 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 6.304E-06 | 1.248E-03 | CYP2A13, CYP2A6 |
BP | GO:0050896; response to stimulus | GO:1901701; cellular response to oxygen-containing compound | 1.616E-05 | 3.060E-03 | BRCA1, CASP1, CYP1B1, MAPK1, NFKB1, PPARD, PTK2B, TLR2, TP53, TSHR |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.888E-05 | 3.484E-03 | CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.888E-05 | 3.484E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.888E-05 | 3.484E-03 | CYP1A1, CYP3A4 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.205E-05 | 4.035E-03 | ATM, CA2, CA7, HTT, MAPK1, NPC1 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.622E-05 | 4.757E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.746E-05 | 4.942E-03 | BRCA1, CASP7, CYP1A1, CYP1B1, MAPK1, NFKB1, NPC1 |
BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 2.991E-05 | 5.252E-03 | CYP1A1, CYP1A2, PTK2B |
BP | GO:0032502; developmental process | GO:0048513; animal organ development | 3.106E-05 | 5.410E-03 | ACHE, ATM, CA2, CYP1A1, CYP1A2, HPGD, HTT, KMT2A, MAPK1, PPARA, PPARD, USP2 |
MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 3.145E-05 | 5.436E-03 | ABCC1, ATM, FABP3, HTT, NPC1 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.770E-05 | 6.315E-03 | CYP1A1, CYP1A2 |
BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 5.195E-05 | 8.258E-03 | ATM, BRCA1, CASP1, FABP4, LMNA, MAPK1, MAPT, NFKB1, PPARA, PPARD, PTK2B, TLR2, TP53 |
BP | GO:0008152; metabolic process | GO:0031058; positive regulation of histone modification | 5.526E-05 | 8.720E-03 | ATM, BRCA1, KMT2A, TP53 |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 5.992E-05 | 9.319E-03 | ATM, CYP1B1, FABP3, KMT2A, LMNA, PPARD, PTK2B, TLR2, TP53 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 6.274E-05 | 9.688E-03 | CYP1A1, CYP3A4 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.276E-22 | 3.566E-18 | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, HBB |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.002E-18 | 4.363E-15 | CA1, CA12, CA13, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.653E-15 | 4.000E-12 | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HBB |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.891E-14 | 9.682E-11 | CYP1A1, CYP1A2, CYP1B1, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.974E-26 | 1.067E-23 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14; CA13 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 8.491E-12 | 6.496E-10 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.215E-11 | 1.129E-09 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.680E-08 | 5.141E-07 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.680E-08 | 5.141E-07 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.153E-06 | 2.206E-05 | CASP7; LMNA; MAPK1; ATM; TP53; NFKB1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.293E-07 | 1.350E-05 | CYP2C9; CYP2A6; CYP1A2; CYP1A1; CYP3A4 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 7.472E-06 | 1.270E-04 | ABCC1; CYP1B1; MAPK1; ATM; BRCA1; TP53; NFKB1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 7.218E-07 | 1.578E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 9.891E-06 | 1.513E-04 | CASP7; CASP1; NFKB1; TLR2 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.850E-05 | 3.633E-04 | PTK2B; MAPK1; TP53; NFKB1; TLR2 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.224E-05 | 1.702E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 3.401E-05 | 4.002E-04 | CASP7; CASP1; MAPK1; NFKB1 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 7.728E-05 | 7.882E-04 | HPGD; KMT2A; ATM; TP53; NFKB1 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.626E-04 | 1.463E-03 | CYP2C9; CYP2D6; MAPK1; CYP2C19 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.120E-04 | 1.802E-03 | ABCC1; MAPK1; TP53; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.141E-04 | 2.529E-03 | MAPK1; PPARA; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 3.419E-04 | 2.562E-03 | RAB9A; TP53; NFKB1; TLR2 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.281E-04 | 1.225E-03 | CYP1A2; CYP1A1; CYP1B1 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.684E-04 | 2.562E-03 | MAPK1; NFKB1; PPARD |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 8.828E-04 | 5.195E-03 | XPO1; CASP1; MAPK1; NFKB1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.674E-04 | 3.774E-03 | MAPK1; TP53; NFKB1 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.442E-03 | 7.357E-03 | MAPK1; BRCA1; TP53; NFKB1; TLR2 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.619E-04 | 4.663E-03 | MAPK1; TP53; NFKB1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.420E-03 | 7.357E-03 | MAPK1; PPARA; NFKB1; TSHR |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 7.619E-04 | 4.663E-03 | MAPK1; NFKB1; TLR2 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.684E-04 | 2.562E-03 | CASP1; MAPK1; NFKB1 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.354E-03 | 7.357E-03 | MAPK1; TP53; NFKB1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.233E-03 | 1.061E-02 | MAPK1; NFKB1; TLR2 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.226E-03 | 6.948E-03 | CASP1; MAPK1; NFKB1 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.115E-03 | 1.044E-02 | MAPK1; NFKB1; TLR2 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.481E-03 | 1.117E-02 | CASP7; MAPK1; NFKB1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 3.487E-03 | 1.442E-02 | MAPK1; MAPT; TP53; NFKB1 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 3.636E-03 | 1.464E-02 | XPO1; ATM; TP53; NFKB1 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.027E-03 | 1.323E-02 | MAPK1; NFKB1; TLR2 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.174E-03 | 1.349E-02 | MAPK1; TP53; NFKB1 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 6.029E-03 | 2.250E-02 | CASP7; PPARA; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 8.083E-03 | 2.653E-02 | CASP7; MAPK1; MAPT |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 9.461E-03 | 2.954E-02 | MAPK1; NFKB1; TLR2 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.050E-02 | 2.976E-02 | TP53; NFKB1; TLR2 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.081E-02 | 2.976E-02 | PTK2B; MAPK1; NFKB1 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.330E-02 | 3.159E-02 | XPO1; TP53; NFKB1 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.348E-02 | 3.159E-02 | MAPK1; TP53; TLR2 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.605E-02 | 3.611E-02 | MAPK1; TP53; NFKB1; PPARD |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.383E-02 | 3.159E-02 | MAPK1; TP53; NFKB1 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 8.323E-03 | 2.653E-02 | MAPK1; TP53 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 7.212E-03 | 2.452E-02 | MAPK1; TP53 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 8.323E-03 | 2.653E-02 | FABP4; TSHR |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 6.683E-03 | 2.378E-02 | CYP1A1; CYP1B1 |
hsa05144 | Malaria_Homo sapiens_hsa05144 | 6.426E-03 | 2.341E-02 | HBB; TLR2 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.013E-02 | 2.976E-02 | MAPK1; TP53 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.109E-02 | 2.976E-02 | MAPK1; TP53 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.537E-03 | 1.780E-02 | MAPK1; TP53 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.013E-02 | 2.976E-02 | CYP2C9; CYP2C19 |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 6.945E-03 | 2.415E-02 | CASP1; TP53 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.096E-02 | 4.582E-02 | PTK2B; MAPK1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.175E-02 | 3.099E-02 | MAPK1; TP53 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.312E-02 | 3.159E-02 | MAPK1; TP53 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.227E-02 | 4.733E-02 | TP53; NFKB1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 5.682E-03 | 2.173E-02 | CYP2A6; CYP3A4 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.109E-02 | 2.976E-02 | NFKB1; TLR2 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.348E-02 | 3.159E-02 | MAPK1; NFKB1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.289E-03 | 1.061E-02 | MAPK1; TP53 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.277E-02 | 3.159E-02 | PPARA; NFKB1 |
hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 1.076E-02 | 2.976E-02 | CASP1; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.383E-02 | 3.159E-02 | MAPK1; NFKB1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.183E-02 | 4.705E-02 | ATM; NFKB1 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.886E-02 | 4.181E-02 | TP53; NFKB1 |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.243E-02 | 3.159E-02 | ATM; TP53 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.312E-02 | 3.159E-02 | CA2; CYP3A4 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.109E-02 | 2.976E-02 | MAPK1; NFKB1 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.853E-05 | 6.396E-04 | CYP2A6; CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; MAPK1; CA9; TLR2; XPO1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
NA: NA | Upper abdominal bloating | NA | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
NA: NA | Dyslipidemia | NA | PPARD |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; MAPT |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
NA: NA | Edema | NA | CA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | PTK2B |
C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ABCC1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
C00-D49: Neoplasms | Cancer | C00-C96 | TP53; MAPK1; CA1; CA9; NFKB1; TLR2; XPO1; ACHE |
C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | ATM |
C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | ABCC1; ABCC1 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |